Eli Mazour’s Post

The rough episode title usually comes to me right after I finish recording an interview for Clause 8 Podcast. However, I had trouble settling on one for this episode because there are so many interesting facets to Erich's story and the priceless advice he shared. He was famously profiled as a patent troll villain in the NYT but is widely admired as a visionary trailblazer in the patent world even by ardent opponents of strong patent rights. One of the most fascinating parts of his story is how he went from running a company and successfully fending off a patent lawsuit for only $500 K by ignoring his litigation lawyers' advice to becoming one of the world's most successful patent monetizers himself. He generously credits his success to being "trained by the best in the business": Ron Katz (the innovator who filed that patent lawsuit), Bob Steinberg of GenerativeIQ (formerly of Latham), and Sean Pak of Quinn Emanuel. https://lnkd.in/eceGnX_X

"Very few people want to start out wearing the black hat. I just embraced it" - Erich Spangenberg. You don't want to miss this Clause 8 podcast episode with the legend of patent monetization. On this episode, Erich shares the story of how being sued for patent infringement led him to embrace the patent monetization field, his strategies for successful patent licensing campaigns, his candid perspective on being labeled a “patent troll,” why big corporations wanted him to work for them, what he thinks the role of generative AI will be for IP, and his plans to buy IPwe out of bankruptcy. https://lnkd.in/eceGnX_X

What’s causing the spike in Section 101 rejections at the USPTO? I spent the last couple of weeks finding out the answer. Also, tips for applicants and practitioners about overcoming the rejections. https://lnkd.in/e3e9_rar

Would you like the USPTO to know whether it's on the right track or the wrong track? Don't miss your chance to participate in Voice of IP's first survey about the state of the USPTO & America's patent system. https://lnkd.in/evjEh7JS

Why does an $850 billion pharma company obtain only 50 patents per year? Steve Caltrider - Chief IP Counsel at Dana-Farber Cancer Institute & Chair of ABA Section of Intellectual Property Law - shares  the story of why and how he relied on data to reduce Eli Lilly’s patent portfolio, and explains why obtaining less patents is likely the better strategy for many large companies. He also discusses the critical role of IP in getting medical innovations to patients, the potentially catastrophic impact of the administration’s march-in proposal, and why all patent attorneys should pay attention to patent policy developments. A must-listen for anyone interested in patent strategy, the potential impact of the administration's recent string of patent-related proposals, or how to succeed as in-house or outside counsel.

Does it seem like you've been getting more Section 101 rejections recently? That's because the USPTO's rate of making 101 rejections in OAs is reaching an all time high this year and is on the cusp of overtaking the pre-2019 PEG (2019 Revised Patent Subject Matter Eligibility Guidance) level of rejections. The most dramatic increase in §101 rejections seems to be in USPTO’s working group 2120, which examines patent applications related to AI. Much more here:

Thank you for coming on Clause 8 Podcast! A must-listen for anyone wondering about what will happen with the EU's SEP proposal.